Adrenocortical carcinoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Ahmed Younes (talk | contribs) No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{RT}} {{AAM}} {{MAD}} | {{CMG}}; {{AE}} {{RT}} {{AAM}} {{MAD}} | ||
==Overview== | ==Overview== | ||
The [[incidence]] of adrenocortical carcinoma is believed to be 0.72 per million cases per year leading to 0.2% of all cancer deaths in the United States and 0.2 to 0.3 per million children per year worldwide but valid data | The [[incidence]] of adrenocortical carcinoma is believed to be 0.72 per million cases per year leading to 0.2% of all cancer deaths in the United States and 0.2 to 0.3 per million children per year worldwide but valid data is lacking. A [[bimodal distribution]] is observed, the first one in [[pediatrics]] and the second one in the fifth to the sixth decade with a predilection for the female gender. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
* The [[incidence]] of adrenocortical carcinoma is | * The [[incidence]] of adrenocortical carcinoma is 7.2 cases per 100,000 individuals per year leading to 0.2% of all cancer deaths in the United States and 3 cases per 100,000 children per year worldwide but valid data is lacking.<ref name="pmid16551738">{{cite journal| author=Allolio B, Fassnacht M| title=Clinical review: Adrenocortical carcinoma: clinical update. | journal=J Clin Endocrinol Metab | year= 2006 | volume= 91 | issue= 6 | pages= 2027-37 | pmid=16551738 | doi=10.1210/jc.2005-2639 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16551738 }}</ref> | ||
=== Age === | === Age === | ||
| Line 14: | Line 14: | ||
=== Gender === | === Gender === | ||
* There is a predilection for the female gender.<ref name="pmid2325710">{{cite journal| author=Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X et al.| title=Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. | journal=N Engl J Med | year= 1990 | volume= 322 | issue= 17 | pages= 1195-201 | pmid=2325710 | doi=10.1056/NEJM199004263221705 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2325710 }}</ref> | * There is a predilection for the female gender.<ref name="pmid2325710">{{cite journal| author=Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X et al.| title=Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. | journal=N Engl J Med | year= 1990 | volume= 322 | issue= 17 | pages= 1195-201 | pmid=2325710 | doi=10.1056/NEJM199004263221705 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2325710 }}</ref> | ||
* Girls are also more commonly affected than boys | * Girls are also more commonly affected than boys with a ratio of 1.6:1.<ref name="pmid14990639">{{cite journal| author=Michalkiewicz E, Sandrini R, Figueiredo B, Miranda EC, Caran E, Oliveira-Filho AG et al.| title=Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 5 | pages= 838-45 | pmid=14990639 | doi=10.1200/JCO.2004.08.085 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14990639 }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 15:46, 17 October 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma epidemiology and demographics |
|
FDA on Adrenocortical carcinoma epidemiology and demographics |
|
CDC on Adrenocortical carcinoma epidemiology and demographics |
|
Adrenocortical carcinoma epidemiology and demographics in the news |
|
Blogs on Adrenocortical carcinoma epidemiology and demographics |
|
Risk calculators and risk factors for Adrenocortical carcinoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Ahmad Al Maradni, M.D. [3] Mohammed Abdelwahed M.D[4]
Overview
The incidence of adrenocortical carcinoma is believed to be 0.72 per million cases per year leading to 0.2% of all cancer deaths in the United States and 0.2 to 0.3 per million children per year worldwide but valid data is lacking. A bimodal distribution is observed, the first one in pediatrics and the second one in the fifth to the sixth decade with a predilection for the female gender.
Epidemiology and Demographics
Incidence
- The incidence of adrenocortical carcinoma is 7.2 cases per 100,000 individuals per year leading to 0.2% of all cancer deaths in the United States and 3 cases per 100,000 children per year worldwide but valid data is lacking.[1]
Age
- A bimodal distribution was observed, the first one in pediatrics and the second one in the fifth to the sixth decade.[2]
Gender
- There is a predilection for the female gender.[3]
- Girls are also more commonly affected than boys with a ratio of 1.6:1.[4]
References
- ↑ Allolio B, Fassnacht M (2006). "Clinical review: Adrenocortical carcinoma: clinical update". J Clin Endocrinol Metab. 91 (6): 2027–37. doi:10.1210/jc.2005-2639. PMID 16551738.
- ↑ Fassnacht M, Allolio B (2009). "Clinical management of adrenocortical carcinoma". Best Pract Res Clin Endocrinol Metab. 23 (2): 273–89. doi:10.1016/j.beem.2008.10.008. PMID 19500769.
- ↑ Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X; et al. (1990). "Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy". N Engl J Med. 322 (17): 1195–201. doi:10.1056/NEJM199004263221705. PMID 2325710.
- ↑ Michalkiewicz E, Sandrini R, Figueiredo B, Miranda EC, Caran E, Oliveira-Filho AG; et al. (2004). "Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry". J Clin Oncol. 22 (5): 838–45. doi:10.1200/JCO.2004.08.085. PMID 14990639.